Takeda Pharmaceutical Company Limited

Takeda Chemical Industries, Inc.

Masaki Hosoya

Shuji Hinuma

Ryo Fujii

Chieko Kitada

Yugo Habata

Shoji Fukusumi

Haruo Onda

Yuji Kawamata

Tetsuya Ohtaki

Kazuhiro Ogi

Yasushi Shintani

Yasunori Miyamoto

Kazuhiko Tatemoto

Takuya Watanabe

Masataka Harada

Yasuko Terao

Yasushi Masuda

Yoshihiro Ishibashi

Norio Shimamoto

Hiromi Yoshida

Masanobu Shoji

Kazuhiro Ohgi

Kuniko Kikuchi

Hideyuki Tanaka

Makoto Kobayashi

Naoki Nishizawa

Shoichi Ohkubo

Yasuaki Ito

Hideki Kizawa

Hideki Matsui

Takeo Moriya

Noriko Yamazoe

Syuji Hinuma

Yuya Kunisada

Shoichi Okubo

Hidetoshi Komatsu

Hiroshi Tanimura

Masanori Miwa

Yuko Noguchi

Disclosed is a production method of pancreatic hormone-producing cells in a form that mimicks the pancreatogenesis, the method comprising subjecting stem cells to the following steps:

Method of producing pancreatic hormone-producing cells

The present invention provides a method of more efficiently producing pancreas cells, particularly pancreatic hormone-producing cells, a method of stably producing pancreas cells in a large amount by more efficiently inducing differentiation of stem cells into pancreas cells, a medicament containing a pancreas cells and a screening method using the cells. A method of producing pancreatic hormone-producing cells, including subjecting stem cells to the following steps (1)-(4):

Method for manufacturing pancreatic-hormone-producing cells

This invention relates to a novel polypeptide involving in the modulation of central nervous system function, circulatory function, immune function, gastrointestinal function, metabolic function, reproductive function, etc., it can be used as a drug for treating or preventing a variety of diseases, e.g. HIV infection or AIDS (acquired immune deficiency syndrome) or the like.

Polypeptides, their production and use

The polypeptides in the present invention possess the effects of promoting and inhibiting the secretion of prolactin, and are thus useful as drugs for the prevention and treatment of various diseases, in terms of prolactin secretion stimulants, which are associated with the secretion of prolactin, such as hypoovarianism, spermatic underdevelopment, menopausal symptoms, hypothyroidism, etc. The polypeptides are useful as drugs for the prevention and treatment of various diseases, in terms of prolactin secretion inhibitors, which are associated with the secretion of prolactin, such as pituitary tumor, diencephalon tumor, menstrual disorder, autoimmune diseases, prolactinoma, sterility, impotence, amenorrhea, lactorrhea, acromegaly, Chiari-Frommel syndrome, Argonz-del Castilo syndrome, Forbes-Albright syndrome, lymphoma, Sheehan's syndrome, spermatogenesis disorder, etc.

Use of a G protein-coupled receptor and its cognizant ligand in the identification of compounds that affect prolactin secretion

The present invention relates to novel peptide derivatives, which are recognized as ligands to G-coupled protein receptor proteins. The peptide of the present invention can be used in (1) development of a receptor binding assay system using the expression system of the recombinant receptor protein and screening of candidates for pharmaceutical compounds, and (2) development of pharmaceutical preparations such as a neutral nerve function regulator, a circulatory function regulator, a cardiac function regulator, an immune function regulator, a digestive organ function regulator, a metabolic function regulator, a generative organ regulator or the like.

Peptides having ligand activities on APJ that is an orphan G protein-coupled receptor, and use thereof

The present invention intends to provide a screening of agonist/antagonist and the like. Specifically, the invention provides a method of screening a compound or its salt that alters the binding property between a novel G protein-coupled receptor protein or its salt, and a substance relating to cholesterol metabolism, which comprises using the receptor protein or its salt, which contains the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 14 or SEQ ID NO: 16, and the substance relating to cholesterol metabolism.

Screening method

The RFRP-3 peptide of the present invention which is an agent for promoting prolactin secretion is useful as a prophylactic and/or therapeutic agent for various diseases associated with prolactin secretion, such as hypoovarianism, seminal vesicle hypoplasia, menopausal syndrome and hypothyroidism.

RFRP-3 and DNA thereof

By using (1) a G protein-coupled receptor protein having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or its salt and (2) a fatty acid or an eicosanoid, a compound or its salt that can change the binding properties of the receptor protein or its salt to the fatty acid or the eicosanoid can be screened efficiently.

G protein-coupled receptor protein, its DNA and ligand thereof

By using a G protein-coupled receptor protein containing an amino acid sequence, which is the same or the substantially the same as an amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:10, SEQ ID NO:12 or SEQ ID NO:14, or its salt together with humanin, a compound or its salt capable of changing the binding properties of the above receptor protein or its salt to humanin can be efficiently screened.

Method of screening therapeutic agents for nerve degeneration associated diseases

The screening method for a compound or a salt thereof that alters the binding property between Neuromedin U or a salt thereof and TGR-1 or a salt thereof, characterized by using Neuromedin U, a derivative thereof or a salt thereof and TGR-1 or a salt thereof, can be useful for screening a therapeutic and/or prophylactic agent for hypertension and stress-related diseases, etc. A TGR-1 antagonist can be useful as a therapeutic and/or prophylactic agent for hypertension and stress-related diseases, etc.

The present invention relates to the ligand polypeptide for the human pituitary- and mouse pancreas-derived G protein-coupled receptor proteins. The ligand polypeptide or the DNA which codes for the ligand polypeptide can be used for (1) development of medicines such as pituitary function modulators, central nervious system function modulators, and pancreatic function modulators, and (2) development of receptor binding assay systems using the expression of recombinant receptor proteins and screening of pharmaceutical candidate compounds. In particular, by the receptor binding assay systems utilizing the expression of recombinant G protein-coupled receptor proteins in accordance with the invention, agonists and antagonists of G protein-coupled receptors which are specific to human and other warm-blooded animals can be screened and the agonists or antagonists obtained can be used as therapeutic and prophylactic agents for various diseases.

Growing community of inventors

Ibaraki, Japan

Masaki Hosoya